Alopecia Areata Market Report 2024: Growth, Trends, Analysis, Outlook, Forecast 2033

The new report published by The Business Research Company, titled Alopecia Areata Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the alopecia areata market size has grown strongly in recent years. It will grow from $3.31 billion in 2023 to $3.55 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The alopecia areata market size is expected to see strong growth in the next few years. It will grow to $4.73 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12596&type=smp

Growing Prevalence Of Hair Loss
The growing prevalence of hair loss is expected to propel the growth of the alopecia areata market going forward. Hair loss is caused by disrupting the body's normal hair growth cycle. Alopecia areata treatment employs corticosteroids, potent anti-inflammatory medications that can inhibit the immune system, to treat a condition where the immune system destroys hair follicles and results in hair loss. For instance, in March 2022, according to an article by the Hair Society, a US-based full-service professional organization, hair loss affected about 21 million women and 35 million men globally. The majority of people in the world will lose their hair starting at age 35, with a 40% loss rate for males and increasing to a 70% loss rate for men at age 80. Women with hair loss will account for 80% or more by age 60. Therefore, the growing prevalence of hair loss is driving the growth of the alopecia areata market.

FDA Approval Marks A Milestone In Innovative Alopecia Areata Treatment
Innovative drug approval is a key trend gaining popularity in the alopecia areata market. Major companies operating in the alopecia areata market are focused on obtaining new drug approvals to strengthen their market position and gain a competitive advantage. For instance, in June 2023, Pfizer Inc., a US-based biotechnology and pharmaceutical company, announced that the US Food and Drug Administration (FDA), a US-based federal agency of the Department of Health and Human Services responsible for protecting public health, had approved LITFULOTM (ritlecitinib), the first and only treatment for severe alopecia areata approved for patients as young as 12. It is a once-daily oral treatment for alopecia areata, an autoimmune condition for which there were previously no FDA-approved treatments for teenagers and few options for adults. LITFULO is a kinase inhibitor that blocks Janus kinase 3 (JAK3) and the tyrosine kinase family of kinases found in hepatocellular carcinoma (TEC).

The alopecia areata market covered in this report is segmented -
1) By Type: Patchy Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Diffuse Alopecia Areata, Ophiasis Alopecia, Other Types
2) By Treatment: Medical Treatments, Natural Treatment, Other Treatments
3) By Diagnosis: Trichoscopy, Skin Biopsy, Other Diagnoses
4) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administration
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12596&type=discount

Major companies operating in the alopecia areata market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Sanofi S.A., GlaxoSmithKline plc., Eli Lilly and Co Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Bausch Health Companies Inc., Incyte Corporation, Dr. Reddy's Laboratories Ltd., Cipla Ltd., Taisho Pharmaceutical Holdings Co. Ltd., Lupin Ltd., Glenmark Pharmaceuticals Ltd., Almirall S.A., Torrent Pharmaceuticals Ltd., Ranbaxy Laboratories Limited, Taro Pharmaceutical Industries Ltd., G&W Laboratories Inc., Vanda Pharmaceuticals Inc., Aclaris Therapeutics Inc., BioSplice Therapeutics Inc., XBiotech Inc., PureTech Health plc, HCell Inc., Histogen Inc.

Contents of the report:
1. Executive Summary
2. Alopecia Areata Market Report Structure
3. Alopecia Areata Market Trends And Strategies
4. Alopecia Areata Market - Macro Economic Scenario
5. Alopecia Areata Market Size And Growth
…..
27. Alopecia Areata Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/alopecia-areata-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.